Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

Imatinib, an ABL tyrosine kinase inhibitor (TKI), has shown clinical efficacy against chronic myeloid leukemia (CML). However, a substantial number of patients develop resistance to imatinib treatment due to the emergence of clones carrying mutations in the protein BCR-ABL. The phosphoinositide 3 ki...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Kitahara, Toshihiko, Kimura, Shinya, Maekawa, Taira, Ohyashiki, Kazuma
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2014
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3928137/
https://ncbi.nlm.nih.gov/pubmed/24100660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.26725
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares